Episode 290: PREMIUM – Empagliflozin and the EMPA-REG OUTCOME study

In episode 290, James and Mike address listener demands for a discussion on the latest diabetes outcomes trial that looked at empagliflozin, a new class of medications for type-2 diabetes. This study actually showed the group who received this new drug had a reduction in CVD events and other clinically important outcomes.


The full content of this Podcast, including the audio file, is available to Premium Members only. Click to find out the benefits of having a Premium Membership.

Why Get A Premium Membership ?